Synthetic Vaccine
Mostrando 13-24 de 287 artigos, teses e dissertações.
-
13. Conservation of nucleotides sequences of bm86 gene and peptides sequences 4822 e 4823, constituents of synthetic vaccine SBm7462 / Conservação de seqüências nucleotídicas do gene bm86 e das seqüências peptídicas 4822 e 4823, constituintes da vacina sintética SBm7462
Rhipicephalus (Boophilus) microplus é um dos mais importantes parasitas de rebanho nas Américas Central e Sul e na Austrália de um ponto de vista econômico. Vacinas derivadas da glicoproteína intestinal Bm86 possuem um amplo potencial como método não químico no controle dos carrapatos. A SBm7462 é uma vacina sintética derivada da Bm86 e possui trê
Publicado em: 2006
-
14. The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome research
The human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic is of unprecedented gravity and is spreading rapidly, notably in the most disadvantaged regions of the world. The search for a preventive vaccine is thus an absolute priority. For over 10 years the French National Agency for AIDS research (ANRS) has been committed to an o
Memórias do Instituto Oswaldo Cruz. Publicado em: 2005-02
-
15. Cellular response in bovine limph nodes inoculated with Anaplasma marginale / Resposta celular em linfonodos de bovinos inoculados com Anaplasma marginale
The immune response against the pathogen Anaplasma marginale was evaluated after the inoculation, in calves, with the strain AUFV1 2nd passage. For this, routine coloration techniques and immunohistochemistry techniques were performed in slides of superficial limph nodes. In the first week post inoculation, a proliferative response was observed in the paraco
Publicado em: 2003
-
16. Resposta imune de bovinos vacinados com peptídeo sintético SBm7462 com vistas ao controle do Boophilus microplus (Canestrini, 1887) / Immune response of vaccinated bovine with synthetic peptide SBm7462 to the control of the Boophilus microplus (Canestrini, 1887)
Bovines of three and four month of old age received monthly and subcutaneously, three immunizations of synthetic peptide SBm7462 emulsified in saponin. The development both cellular and humoral immune response were evaluated. Its was achieved identifying the IgG1 and IgG2 antigen specific isotypes, determining of the profile of circulating lymphocytes (CD4+,
Publicado em: 2003
-
17. Utilization of biodegradable PLGA microspheres as a delivery system for synthetic vaccine SBm7462 on control of the Boophilus microplus (Canestrini, 1887): experimental model in mice / Utilização de microesferas biodegradáveis PLGA como sistema de liberação para a vacina sintética SBm7462 no controle do Boophilus microplus (Canestrini, 1887): modelo experimental em camundongos
Foi avaliada a resposta imunológica do peptídeo sintético SBm7462 emulsificado com o adjuvante saponina ou encapsulado em microesferas biodegradáveis PLGA; bem como, a do peptídeo sintético SPf66 encapsulado no referido sistema de liberação. O estudo foi realizado com camundongos Balb/c, fêmeas, utilizando-se uma dose de 100 mg de peptídeo por anim
Publicado em: 2003
-
18. Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity
The main objective of the present study was to assess the specificity and sensitivity of a modified assay using short synthetic peptides of the V3 region of HIV-1 gp120, which is the main target for neutralizing antibodies. Results from an enzyme immunoassay (EIA) employing a panel of synthetic peptides of HIV-1 subtypes and using urea washes to detect high
Brazilian Journal of Medical and Biological Research. Publicado em: 2002-03
-
19. Antigenicity and Immunogenicity of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b
Polysaccharide-protein conjugates as vaccines have proven to be very effective in preventing Haemophilus influenzae type b infections in industrialized countries. However, cost-effective technologies need to be developed for increasing the availability of anti-H. influenzae type b vaccines in countries from the developing world. Consequently, vaccine product
American Society for Microbiology.
-
20. Towards a Synthetic Pneumococcal Vaccine: Synthetic Oligosaccharides as Tools for Improving the Specificity of Enzyme-Linked Immunosorbent Assays
American Society for Microbiology (ASM).
-
21. Induction of biologically active antibodies by a polyvalent synthetic vaccine constructed without carrier.
Four synthetic peptides that copy fragments of two bacterial antigens (Streptococcus pyogenes M protein and diphtheria toxin), one viral antigen (hepatitis B surface antigen), and one parasitic antigen (circumsporozoite protein of Plasmodium knowlesi) were covalently bound within the same construct. This totally synthetic polyvalent administered to mice with
-
22. Prospects for total synthesis: A vision for a totally synthetic vaccine targeting epithelial tumors
Vaccines derived from totally synthetic carbohydrate antigens have been shown to elicit an immune response in both preclinical and clinical settings. The vaccines have been proven safe when administered in human clinical trials and are also competent at inducing antibodies that react with aberrant cells expressing the corresponding carbohydrate antigen. The
National Academy of Sciences.
-
23. First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.
A synthetic peptide vaccine which protects dogs against challenge with virulent canine parvovirus is described. The amino acid sequence used was discovered in previous studies on the immunogenic properties of previously mapped antigenic sites and represents the amino-terminal region of viral protein VP2. As with marker vaccines, it is possible to discriminat
-
24. Comparison of a whole-virus enzyme immunoassay (EIA) with a peptide-based EIA for detecting rubella virus immunoglobulin G antibodies following rubella vaccination.
A total of 250 human serum samples were tested for rubella virus immunoglobulin G antibodies by two enzyme immunoassays (EIAs), one using whole rubella virus antigen and the other based on the use of synthetic peptide antigen. The samples were taken from 125 volunteers before and after their immunization with the RA 27/3 rubella vaccine. This study indicates